Kymera Therapeutics IncNASDAQ:KYMR
- LAST PRICE46.8500
- TODAY'S CHANGE (%)-0.0100 (-0.0213%)
- Bid / Lots44.1400/ 1
- Ask / Lots51.3600/ 1
- Open / Previous Close47.0000 / 46.8600
- Day Range
- 52 Week Range
- Volume184,881
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KYMR |
|---|---|---|
| 09:32 ET | 1923 | 47.015 |
| 09:33 ET | 300 | 47.085 |
| 09:35 ET | 700 | 46.87 |
| 09:37 ET | 100 | 46.74 |
| 09:42 ET | 1300 | 46.455 |
| 09:44 ET | 400 | 46.49 |
| 09:46 ET | 400 | 46.465 |
| 09:48 ET | 517 | 46.435 |
| 09:50 ET | 200 | 46.44 |
| 09:51 ET | 600 | 46.63 |
| 09:53 ET | 300 | 46.65 |
| 09:55 ET | 400 | 46.7375 |
| 10:02 ET | 500 | 46.555 |
| 10:04 ET | 100 | 46.87 |
| 10:06 ET | 800 | 46.88 |
| 10:08 ET | 1300 | 46.94 |
| 10:09 ET | 1576 | 46.9375 |
| 10:11 ET | 500 | 46.935 |
| 10:13 ET | 6729 | 47.01 |
| 10:15 ET | 1100 | 46.92 |
| 10:18 ET | 300 | 46.78 |
| 10:20 ET | 100 | 46.74 |
| 10:22 ET | 300 | 46.845 |
| 10:26 ET | 500 | 46.855 |
| 10:27 ET | 300 | 46.79 |
| 10:31 ET | 200 | 46.8 |
| 10:33 ET | 300 | 46.835 |
| 10:36 ET | 100 | 46.74 |
| 10:38 ET | 100 | 46.74 |
| 10:40 ET | 854 | 46.55 |
| 10:42 ET | 118 | 46.695 |
| 10:44 ET | 100 | 46.72 |
| 10:47 ET | 200 | 46.76 |
| 10:49 ET | 100 | 46.745 |
| 10:51 ET | 200 | 46.84 |
| 10:54 ET | 400 | 46.8 |
| 10:56 ET | 200 | 46.83 |
| 10:58 ET | 100 | 46.84 |
| 11:00 ET | 1100 | 46.7 |
| 11:02 ET | 100 | 46.64 |
| 11:05 ET | 106 | 46.69 |
| 11:09 ET | 100 | 46.715 |
| 11:12 ET | 100 | 46.73 |
| 11:14 ET | 570 | 46.57 |
| 11:18 ET | 200 | 46.47 |
| 11:20 ET | 200 | 46.46 |
| 11:21 ET | 500 | 46.49 |
| 11:23 ET | 143 | 46.5 |
| 11:25 ET | 539 | 46.75 |
| 11:27 ET | 1100 | 46.47 |
| 11:30 ET | 274 | 46.49 |
| 11:32 ET | 100 | 46.49 |
| 11:34 ET | 100 | 46.34 |
| 11:36 ET | 100 | 46.31 |
| 11:39 ET | 630 | 46.46 |
| 11:41 ET | 501 | 46.395 |
| 11:43 ET | 400 | 46.43 |
| 11:45 ET | 300 | 46.475 |
| 11:48 ET | 100 | 46.475 |
| 11:50 ET | 525 | 46.475 |
| 11:52 ET | 400 | 46.505 |
| 11:54 ET | 1400 | 46.43 |
| 11:56 ET | 400 | 46.555 |
| 11:57 ET | 300 | 46.615 |
| 12:01 ET | 200 | 46.65 |
| 12:03 ET | 300 | 46.72 |
| 12:06 ET | 400 | 46.72 |
| 12:08 ET | 310 | 46.73 |
| 12:10 ET | 200 | 46.8 |
| 12:12 ET | 600 | 46.705 |
| 12:14 ET | 800 | 46.52 |
| 12:15 ET | 400 | 46.48 |
| 12:17 ET | 500 | 46.51 |
| 12:19 ET | 500 | 46.54 |
| 12:21 ET | 500 | 46.68 |
| 12:24 ET | 100 | 46.67 |
| 12:26 ET | 200 | 46.7 |
| 12:28 ET | 200 | 46.74 |
| 12:30 ET | 400 | 46.69 |
| 12:32 ET | 200 | 46.85 |
| 12:33 ET | 1803 | 46.82 |
| 12:35 ET | 1600 | 46.77 |
| 12:37 ET | 700 | 46.7575 |
| 12:39 ET | 800 | 46.91 |
| 12:42 ET | 700 | 46.8 |
| 12:44 ET | 200 | 46.87 |
| 12:46 ET | 1530 | 46.86 |
| 12:48 ET | 700 | 46.795 |
| 12:50 ET | 511 | 46.92 |
| 12:51 ET | 2211 | 46.83 |
| 12:53 ET | 700 | 46.865 |
| 12:55 ET | 1162 | 46.83 |
| 12:57 ET | 2300 | 46.9 |
| 01:00 ET | 54221 | 46.85 |
Nov 26, 2024
Kymera Therapeutics to Participate in Upcoming December Investor Conferences, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 18, 2024
DJ Kymera Therapeutics Initiated at Overweight by Stephens & Co., from 10:26AM ET on Monday Nov 18, 2024 by Dow Jones
10:26AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 6, 2024
DJ Kymera Therapeutics Is Maintained at Equal-Weight by Morgan Stanley, from 7:37AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:37AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Kymera Therapeutics to Participate in Upcoming November Investor Conferences, from 7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
DJ Kymera Therapeutics Is Maintained at Buy by UBS, from 11:10AM ET on Monday Nov 04, 2024 by Dow Jones
11:10AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kymera Therapeutics Inc | 3.0B | -20.1x | --- |
Merus NV | 3.1B | -11.5x | --- |
SpringWorks Therapeutics Inc | 3.1B | -10.7x | --- |
Edgewise Therapeutics Inc | 3.0B | -22.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Protagonist Therapeutics Inc | 2.6B | 16.4x | --- |
Company Information
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Contact Information
- Headquarters
- 500 North Beacon Street, 4Th FloorWATERTOWN, MA, United States 02472
- Phone
- 857-285-5314
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Bruce Booth
- President, Chief Executive Officer, Co-Founder, Director
- Nello Mainolfi
- Chief Financial Officer
- Bruce Jacobs
- Chief Operating Officer
- Jeremy Chadwick
- Chief Medical Officer
- Jared Gollob
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
|---|---|
Revenue (TTM) | $87.6M |
Shares Outstanding | 64.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $-2.33 |
Book Value | $7.11 |
P/E Ratio | -20.1x |
Price/Sales (TTM) | 34.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -228.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
